List of Xuriden drug patents
Xuriden is owned by Wellstat Therap.
Xuriden contains Uridine Triacetate.
Xuriden has a total of 1 drug patent out of which 0 drug patents have expired.
Xuriden was authorised for market use on 04 September, 2015.
Xuriden is available in granule;oral dosage forms.
The generics of Xuriden are possible to be released after 10 July, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6258795 | WELLSTAT THERAP | Acylated uridine and cytidine and uses thereof |
Jul, 2023
(3 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 4, 2022 |
Drugs and Companies using URIDINE TRIACETATE ingredient
Market Authorisation Date: 04 September, 2015
Treatment: NA
Dosage: GRANULE;ORAL
More Information on Dosage
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic